NVCT:NASDAQ, Nuvectis Pharma, Inc.
NVCT stock overview
Nuvectis Pharma, Inc. (NVCT:NASDAQ) closed at $18.76 on October 15, 2026,
up 4.22% on the day.
The stock trades 35.9% below its 52-week high of $29.28
and 238.0% above its 52-week low of $5.55.
Over the past year, it gained 195.6%.
Nuvectis Pharma, Inc. is part of the Health Care sector.
Key figures
- Price
- $18.76
- Day change
- +4.22%
- Volume
- 6,223
- Average volume
- 215,204
- Market cap
- 612M+
- 52-week range
- $5.55 – $29.28
- 50-day average
- $21.62
- 200-day average
- $13.95
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -8.58% |
-17.88% |
-5.96% |
+116.09% |
+195.57% |
Price action over the past year
In 252 trading sessions since October 14, 2025, NVCT closed higher on 137 days (54%).
Its best day was June 24, 2026 (+39.49%) and its worst was June 30, 2026 (-35.54%).
The stock moved 10% or more in a single session 10 times.
Recent signals
NVCT news
-
Oct 9, 2026:
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
-
Sep 25, 2026:
Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead Asset
-
Sep 24, 2026:
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
-
Sep 3, 2026:
Nuvectis Pharma To Participate in Upcoming Investor Conferences
-
Sep 3, 2026:
Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)
-
Aug 19, 2026:
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
-
Aug 4, 2026:
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
-
Jul 29, 2026:
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
About Nuvectis Pharma, Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its pipeline products include NXP800, NXP900.
Find more stocks like NVCT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.